Clinical Trial Update: INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation

View source ↗

Summary

The real-world INREAL study reports results of nintedanib (Ofev) in patients with chronic fibrosing interstitial lung disease with a progressive phenotype, focu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrosing Interstitial Lung Disease
• Interstitial Lung Disease

Drugs mentioned

• OFEV (Nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Lung Diseases, Interstitial | Status: COMPLETED | Results posted: 2025-04-25